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Abstract
Objectives: Neurokinin B (NKB) and kisspeptin are obligate for normal gonadotropin secretion, and links between GnRH pulsatility and vasomotor symptoms have been proposed. Using a selective NKB receptor (NK3R) antagonist, the role of NKB in the hypergonadotropic state in menopausal women was explored.

Methods: Eleven postmenopausal women were administered the NK3R antagonist MLE4901, 40mg twice daily orally for 7 days. 10-minute blood sampling for 8 hr was performed before and on the last day of NK3R antagonist treatment for LH pulsatility analysis with kisspeptin-10 (0.3 µg/kg iv bolus) administered at 6 hr on both days. Hot flash frequency and severity were self-reported for 7 days before and during NK3R antagonist administration.

Results: LH fell from 29.3±4.1 to 24.4±3.8 IU/l (p<0.05) after 7 days of NK3R antagonist, with no change in FSH. Basal (nonpulsatile) LH secretion was reduced (549.0±70.8 vs 366.1±92.1 IU/l/6hr, p=0.006) and while LH pulse frequency did not change in the group as a whole (0.8±0.1 to 0.7±0.1 pulses/hr, ns), it did fall in the 8/11 women with hot flashes, (1.0±0.1 to 0.7±0.1 pulses/hr, p<0.05). These women also reported a reduction in hot flash frequency (3.4±1.2 to 1.0±0.6 hot flashes/day, p=0.008) whist taking NK3R antagonist. Kisspeptin-10 did not affect LH secretion with or without NK3R antagonist.

Conclusions: The administration of a NK3R antagonist indicates a role for NKB in the regulation of LH/GnRH in postmenopausal women whereas the lack of response to kisspeptin may reflect the hypoestrogenic state.  These data support a link between LH/GnRH pulsatility and vasomotor symptoms and NK3R antagonism as a potential therapeutic approach. 





Introduction
Recent years have seen substantial increases in understanding of the regulation of the secretion of gonadotropin-releasing hormone (GnRH) and thus of the hypothalamo-pituitary-gonadal axis, following the discovery of the involvement of the hypothalamic neuropeptides kisspeptin and neurokinin B (NKB) and their receptors  ADDIN EN.CITE ().  Several studies have shown stimulatory effects of kisspeptin on LH secretion in men and women, the response in healthy women being variable and dependent on sex-steroid milieu across different phases of the menstrual cycle  ADDIN EN.CITE (, ) with a direct positive correlation with estradiol concentrations  ADDIN EN.CITE (, ). Administration of NKB did not affect LH secretion in men or women  ADDIN EN.CITE (). Although both kisspeptin and NKB are co-expressed in some hypothalamic neurones  ADDIN EN.CITE () which also co-express dynorphin and are termed KNDy neurones, NKB action appears to be upstream of kisspeptin as patients with inactivating mutations of NKB and its cognate receptor show diminished LH pulsatility, which is restored by kisspeptin-10 infusion (). A recent study of the effect of the neurokinin 3 receptor antagonist (NK3R) MLE4901 (previously termed AZD4901) in women with polycystic ovary syndrome (PCOS) showed some suppression of LH secretion  ADDIN EN.CITE (), also demonstrated in normal women administered exogenous estrogen ().   
The only study administering kisspeptin-10 in estrogen deficient postmenopausal women showed a rather limited LH response to both kisspeptin-10 and GnRH injection compared to women in the follicular phase or those taking hormonal contraception (). This suggests that endogenous kisspeptin might already be operating at its maximal capacity to increase GnRH pulsatility and subsequently LH secretion in response to the loss of ovarian negative feedback in postmenopausal women. In keeping with this, hypothalamic expression of KISS1 and TAC3 mRNA (encoding kisspeptin and NKB respectively) are upregulated, and kisspeptin and neurokinin B neurones are hypertrophied in the infundibular nucleus of postmenopausal compared to premenopausal women  ADDIN EN.CITE (). Similarly, the expression of those neuropeptides is increased in ovariectomised rodents, ewes and monkeys but restored with estrogen replacement  ADDIN EN.CITE (, ). 
In ovariectomised ewes and castrate monkeys, selective blockade of NK3R decreased the frequency of LH pulses (indicative of pulsatile GnRH release) and similar effects were found in women with PCOS, also characterised by higher LH pulse frequency  ADDIN EN.CITE (, , ). However, the inhibitory effect of such blockade on the NKB/KP/GnRH pathway on high LH secretion in healthy women, such as post menopausally, has not been explored. Manipulation of high LH/GnRH pulsatility in postmenopausal women may open new paradigms in the management of menopausal hot flashes since functional links between pathways driving GnRH pulsatility and vasomotor symptoms have been proposed (). Synchronisation of LH pulses with hot flashes in women has been demonstrated  ADDIN EN.CITE (, ), and administration of exogenous neurokinin B induced hot flash-like symptoms in healthy premenopausal women  ADDIN EN.CITE (). Using a selective NK3R antagonist, the role of neurokinin B in the regulation of hypergonadotropic state in menopausal women and its interaction with kisspeptin was therefore investigated. 

Materials and Methods
Participants
Eleven healthy postmenopausal women, aged 46-62 years and 2-20 years since natural menopause were recruited to this study. All subjects provided informed written consent and the study received approval from the Lothian Research Ethics Committee (Ref: 09/S1101/67). Subjects were on no hormonal replacement therapy and not taking any preparations for hot flashes. As the primary outcome was analysis of LH secretion, the presence or frequency of hot flashes were not inclusion criteria, and were reported in 8 of the subjects. Full blood count, renal function, electrolytes, liver function and electrocardiogram were within normal limits. 
Study drugs
The specific NK3R antagonist MLE4901 was administered orally at 40 mg twice daily. Human kisspeptin-10 (KP-10) was custom synthesized under GMP standards (Bachem GmBH, Weil am Rhein, Germany). 1 mg KP-10 was dissolved in 5 ml sterile 0.9% saline immediately before administration as an intravenous bolus of 0.3 µg/kg. 
Protocol
A schematic representation of the protocol is shown in Figure 1. Subjects were administered the NK3R antagonist for 7 days. Peripheral venous blood was sampled for spot LH and FSH 24 hours before treatment and after NK3R antagonist had been administered for 1, 3, 5 and 7 days.  Once daily blood sampling was performed in the morning: during treatment, this was immediately prior to the next dose of NK3R antagonist, i.e. 12 hours after the previous dose.
On the pre-treatment day and on the last day of NK3R antagonist administration the subjects attended the clinical research facility for 8 hours. All visits commenced between 0800 and 0900 hours. The last dose of NK3R antagonist was administered, following which, blood samples were collected via an indwelling intravenous cannula at 10 min intervals for 6 hours for the assessment of LH pulsatility. Kisspeptin-10 was administered after 6 hours with further blood sampling for 2 hours every 10 min for LH and hourly for FSH. 
Subjects were asked to self-report any flashing symptoms (e.g. heat and sweating) and night-time awakenings, including their frequency and perceived severity (1 ‘mild’= heat sensation and no sweating; 2 ‘moderate’= heat and sweating, not causing disruption to activity; 3 ‘severe’ = heat and sweating, disrupting activity) by using daily diaries for a week prior to study visits and whilst on NK3R antagonist treatment. Subjects were encouraged to record the flash and its severity as it occurred to minimise retrospective monitoring. The subjective hot flash-related daily interference scale (HFRDIS) (), covering the preceding 7 days, was completed by the subjects on the last day pre-treatment and on completion of NK3R antagonist treatment. 
Safety blood samples including full blood count, renal function and electrolytes, and liver function were drawn before commencing the NK3R antagonist, 2-3 weeks after the treatment had finished and at the end of each 8 hour visit for frequent blood sampling.   Hormone assays, blinded LH pulsatility measurement and safety blood tests were performed as previously described  ADDIN EN.CITE (, ). 
Statistical analysis
Mean LH and FSH concentrations over time were compared using one-way ANOVA followed by Bonferroni’s multiple comparisons post hoc analysis. Area under the curve (AUC) LH and FSH during 8 hours of frequent LH sampling (every 10 minutes) and FSH sampling (every hour) was determined by trapezoid integration on the pre-treatment day (control) and on day 7 of NK3R antagonist administration. Comparisons in AUC across time and between the groups were performed using repeated-measures two-way ANOVA with Bonferroni’s multiple comparison post hoc analysis. AUC LH and FSH response to kisspeptin-10 administration was not calculated for one of the eleven women, as full 2-hour sampling data post kisspeptin-10 injection was not obtained. 
Data were tested for normality by Shapiro-Wilk normality test. Parameters of LH pulsatility were compared by paired Student’s t-test (for normally distributed data: secretory mass per pulse, basal and pulsatile secretion, ApEn (approximate entropy, a measure of the orderliness of pulsatility) or Wilcoxon matched-pairs signed rank test (for data that did not have a normal distribution: pulse frequency). 
Paired mean frequency of hot flashes and night-time awakenings were compared using Wilcoxon matched-pairs signed rank test. Mean flash severity scores (unpaired as score was set to missing on the day that hot flashes equalled zero) were compared using Mann-Whitney test. Total and individual item HFRDIS scores were compared by Wilcoxon matched-pairs signed rank test. The time-course of hot flash frequency changes across 7 days of NK3R antagonist treatment was analysed by Friedman test followed by Dunn’s multiple comparison post hoc analysis. Data are presented as mean ± SEM.

Results
MLE4901 was well tolerated with no treatment discontinuations. Haematology and biochemistry safety parameters remained stable in all subjects throughout the study period. Tablet returns did not indicate any non-compliance.

NK3R antagonism decreases LH but not FSH secretion
MLE4901 had an overall suppressive effect on LH secretion when measured once daily (ANOVA p=0.008), with a significant fall after 7 days of treatment (pre-treatment 29.5±4.1 vs 24.4±3.8 IU/l day 7, p<0.05, Fig. 2A). There was no difference from pre-treatment on other sampling days. However a more detailed analysis of 10-minute sampling of LH secretion over 6 hours pre-treatment and on day 7 of NK3R antagonist administration showed no difference in AUC LH (Fig. 2B). FSH secretion was unchanged by the NK3R antagonist (Fig. 2C).

NK3R antagonist modulates pulsatile LH secretion in postmenopausal women
Examples of LH pulse frequency profile are shown in figure 3 (A, G). Deconvolutional analysis showed that NK3R antagonist treatment decreased basal (i.e. nonpulsatile) LH secretion (p=0.006) although LH pulse frequency did not change with NK3Ra in the group as a whole (0.8±0.1 vs 0.7±0.1 pulses/hr, ns) (Fig. 3B and C). Secretory mass per LH pulse was increased with NK3R antagonist treatment (p=0.01) (Fig. 3D) with no overall effect on total amount of LH secreted in a pulsatile manner (Fig. 3E) and there was no change in ApEn (Fig. 3F).
However in a secondary analysis of the 8 of 11 women with self-reported symptomatic hot flashes, NK3R antagonist reduced both basal LH secretion (p=0.03) and the frequency of LH pulses (1.0±0.1 vs 0.7±0.1 pulses/hr, p<0.05) (Fig. 3H and I). The mass of LH per pulse was increased (p=0.04), although pulsatile LH secretion remained unchanged (Fig. 3J and K). The orderliness (ApEn) of LH secretory pattern was unaffected by treatment in those with flash symptoms (Fig. 3L). 

Kisspeptin-10 does not elicit gonadotropin response with or without NK3R antagonist 
Intravenous kisspeptin-10 was administered at 6 hours during the frequent sampling protocol, with 2 hours sampling thereafter.  Kisspeptin-10 had no effect on AUC LH or FSH secretion in postmenopausal women, both pre-treatment and after 7 days treatment with NK3R antagonist treatment (Fig. 4). 

NK3R antagonist reduces self-reported postmenopausal hot flashes
Hot flash frequency, severity and interference with daily activities were recorded in the 8 of 11 postmenopausal women experiencing these symptoms, for 7 days pre-treatment and whilst taking NK3Ra. These women reported a reduction in hot flash frequency (3.4±1.2 to 1.0±0.6 hot flashes/day, p=0.008) and night-time awakenings caused by flashes (1.6±0.3 to 0.4±0.2 awakenings/night, p=0.008) during the 7 days of taking the NK3R antagonist (Fig. 5A-B). There was also an improvement in the severity of flashing symptoms from moderate to mild (mean severity 2.1±0.2/3 vs 1.4±0.1/3, p=0.03) with the NK3R antagonist (Fig. 5C). The time-course of changes in day-time hot flashes across 7 days of NK3R antagonist administration was analysed (p<0.0001), showing significantly lower hot flash frequency on the 2nd day of treatment (p<0.05 vs baseline) and thereafter each day for the remainder of NK3Ra administration (p<0.05 at day 3-7 vs baseline) (Fig. 5D). Night-time awakenings as a result of those flashes also showed a rapid decrease in frequency with the NK3R antagonist and were reduced throughout treatment (p=0.0003) (Fig. 5E). 
NK3R antagonist reduced total hot flash-related daily interference scale (HFRDIS) score (31.3±7.7 vs 9.0±4.7, p=0.008), indicating significantly reduced interference of hot flashes with daily function (Table 1). The highest mean interference rating was noted for sleep, which was improved by the NK3R antagonist (6.4±0.8 vs 1.1±0.6, p=0.008). Whilst all other individual HFRDIS items also showed a reduction in their interference scores, they did not reach statistical significance. 






Discussion
This study has investigated the role of neurokinin B and its interaction with kisspeptin in the regulation of GnRH and LH secretion in postmenopausal women. Selective blockage of NK3R signalling had a limited suppressive effect on LH secretion as assessed by once daily sampling with no detected effect on FSH release. Blood sampling during drug administration was before the morning dose; as the half-life of MLE4901 (termed AZD4901 at that time) is approximately 8.5 hours  ADDIN EN.CITE (), this may have reduced the ability of this sampling schedule to detect suppression. This is supported by detailed analysis of pulsatile LH secretion on the last day of drug administration which revealed a marked effect of the NK3R antagonist on parameters of pulsatile secretion (Fig 3), which were measured over 6 hours immediately following drug administration. This confirms a role for NK3R signalling in mediating the LH hypersecretion characteristic of the post-menopausal state. The physiological role of NKB on pulsatile GnRH secretion is further supported in a subgroup of women experiencing hot flashes where a reduction in LH pulse frequency was identified. These women also reported a marked reduction in flash symptoms whilst on NK3R antagonist consistent with a link between GnRH pulsatility and vasomotor symptoms ().
These data show that, in postmenopausal women, NK3R antagonist decreased LH but not FSH secretion. This pattern of effect of NK3R antagonist is consistent with data from patients with inactivating mutations in NKB or its cognate receptor who display reduced LH levels but near normal FSH secretion, likely mediated through decreased GnRH pulse frequency (). While the present study has shown that in postmenopausal women high LH output can be altered by the NK3R antagonist, LH pulse frequency in the group as a whole, the proportion of total LH secreted in pulses and the regularity of LH secretion were not affected. Mass of LH secreted per pulse was increased with the NK3R antagonist, although this may be due to LH pulses merging in postmenopausal women without return to basal secretion thereby giving an apparent greater LH secretory mass per pulse. These findings differ from the decreased frequency of LH pulses seen in in women with PCOS  ADDIN EN.CITE (), pre-menopausal women () and in ovariectomised ewes (). Duration and/or dose of NK3R antagonist administration in this study may have contributed to the limited suppressive effect seen on LH/GnRH secretion in contrast to hypogonadotropic hypogonadism observed in patients with loss-of-function mutations in NKB and its receptor () or NK3R antagonist administration for 4 weeks in women with PCOS  ADDIN EN.CITE (). The more limited effect of NK3R antagonist on the high LH secretion in menopausal women may also reflect the consequences of long-term estrogen depletion, as increased TAC3 expression has been reported in the hypothalamus of postmenopausal women, with hypertrophy of NKB neurones. Increased expression of hypothalamic Tac3 mRNA after ovariectomy in animal models is restored with estrogen replacement  ADDIN EN.CITE (), and sex-steroid receptors have been localised to NKB perikarya  ADDIN EN.CITE (, ). These data clearly support a role of estrogenic feedback in the regulation of NKB signalling in the hypothalamus, and it seems plausible that loss of negative estrogen feedback following the menopause and a subsequent increase in NKB signalling impedes the ability to manipulate the NKB/Kp/GnRH pathway as readily as in other states. The duration of estrogen withdrawal as well as species difference complicate direct comparison of these results, especially since there is anatomical variation in pathways mediating sex-steroid feedback between humans and other mammals  ADDIN EN.CITE (, ).
Interestingly, the NK3R antagonist reduced LH pulse frequency in postmenopausal women reporting hot flashes. It is however unclear as to whether NKB acts to modulate LH/GnRH pulsatility specifically in those experiencing flash symptoms as larger groups would be required to explore this more robustly. In this study, postmenopausal women were not recruited based on having hot flashes and statistical comparisons between those with and without flashing were not feasible since there were only 3 women in the latter subgroup. Small sample size may have impacted overall effect seen on LH pulsatility. It is however possible that the NKB/GnRH pathway is somewhat different and is enhanced in women with hot flashes, thereby being more responsive to suppression by the NK3R antagonist. NKB signalling may therefore be a common pathway regulating both vasomotor symptoms and GnRH/LH pulsatility.
The lack of effect of kisspeptin-10 on gonadotropin secretion seen in this study is consistent with previous data showing a minimal LH response to both kisspeptin-10 and GnRH injection in post-menopausal women as opposed to women in the early follicular phase of the menstrual cycle or taking hormonal contraceptives (), or during estrogen administration where this dose of kisspeptin-10 was able to induce surge-like LH secretion (). In premenopausal women, the response to kisspeptin-10 is directly and positively related to serum estradiol concentrations  ADDIN EN.CITE (, ). This further highlights the role of sex-steroid feedback in the control of hypothalamic neuropeptide signalling. It seems likely that due to loss of negative estrogen feedback post menopause, the kisspeptin system is already operating at its maximum to increase GnRH and LH secretion with little scope for any additional stimulatory effect of exogenous kisspeptin. This is supported by hybridization histochemistry showing that in the postmenopausal infundibular nucleus kisspeptin neurones are hypertrophied, there are more of them and they have increased expression of KISS1 as well as TAC3 mRNA  ADDIN EN.CITE (). The absence of an effect of kisspeptin-10 on LH alone or in the presence of NK3R antagonism precludes clear analysis of the hierarchical relationship between kisspeptin and NKB in the postmenopausal women, although it would be of interest to repeat the experiment in postmenopausal women taking estrogen replacement. The same batch of kisspeptin-10 was effective in contemporaneous studies in premenopausal women (). In patients with inactivating mutations in TAC3 or TAC3R, kisspeptin-10 was able to restore LH pulse frequency to normal and increase LH AUC (), and we have recently shown that in pre-menopausal women in a model of the LH surge this NK3R antagonist truncated the response to kisspeptin-10 (). Thus while NKB signalling appears to be predominantly proximal to kisspeptin signalling, as also indicated in animal and human studies  ADDIN EN.CITE (, , ), there is a complex interaction between these pathways. 

The finding that all postmenopausal women with symptomatic flashes (8/11) reported a reduction in the frequency of total and night-time hot flashes whilst on NK3R antagonist and an improvement in their severity is a striking and novel finding. The response to NK3R antagonist in the reduction of flash symptoms was also a rapid one, with a significant fall in both day time and night time symptoms after only 2 days of treatment. The NK3R antagonist also reduced the interference of those flashes with daily activities. The present data provide evidence to implicate NKB as a key link between sex-steroid deficiency and hot flashes, as proposed from studies in animal models (). In premenopausal women neurokinin B itself administered as an intravenous infusion over 30 minutes induced the sensation of heat, which was accompanied by increased heart rate and skin conductance, resembling events associated with menopausal hot flashes  ADDIN EN.CITE (). Moreover, a recent genome-wide association study has localised single-nucleotide polymorphisms associated with vasomotor symptoms to the neurokinin 3 receptor locus (TAC3R) (). Reduced cutaneous vasodilation in rodents with ablation of NKB-expressing neurones  ADDIN EN.CITE () and lowered body core temperature in NK3R antagonist treated sheep  ADDIN EN.CITE () lend further support for the involvement of NKB signalling in hot flashes. Reduction in the frequency of LH pulses by the NK3R antagonist observed here in the group of women with flash symptoms suggests the mechanism of flashes to be tied to the hypothalamic control of pulsatile GnRH secretion. This is consistent with studies showing the synchronization of LH pulses with hot flashes in women  ADDIN EN.CITE (). Although these data support the involvement of NKB in vasomotor symptoms, it is possible that separate pathways exist mediating hot flashes and those associated with pulsatile GnRH/LH secretion, with both involving NKB regulation. 
The limitation of the absence of a placebo group in the present study is acknowledged, as well as the small number of women studied. Placebo has been shown to reduce hot flashes by 20-30% within 4 weeks of treatment and in 15% of women experiencing symptomatic flashes  ADDIN EN.CITE (, ). In contrast, NK3R antagonist administration in this study was associated with an approximately 70% reduction in hot flashes over only 7 days of treatment, in all 8 women reporting hot flashes. Objective assessment of menopausal hot flashes, such as using skin conductance monitors, might have reinforced these findings. This group had a lower hot flash frequency than is generally the case in studies specifically investigating therapies for that condition (), reflecting recruitment criteria not specifying the presence of or a minimum flash frequency.  
In summary, the secretion of LH was reduced in post-menopausal women by administration of a NK3R antagonist but the absence of a response to kisspeptin-10 precluded investigation of the relationship between the NKB and kisspeptin pathways in the post-menopause. We have shown that NK3R antagonist treatment reduced subject reported menopausal hot flashes and reduced the frequency of LH pulses in those women. These data demonstrate that NKB signalling is involved in the regulation of LH secretion in the hypergonadotropic state of the menopause and provide indirect evidence linking vasomotor symptoms and high GnRH pulse frequency to the NKB pathway. Our studies on a relatively small number of post-menopausal women suggest that NK3R antagonism may have clinical application in the management of hot flashes. 
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Figure 1. Study protocol. 11 healthy postmenopausal women were administered NK3R antagonist MLE4901 orally for 7 days. LH and FSH were measured throughout the study. LH pulsatility was assessed during 10 minute blood sampling for 6 hours on the day before and on the last day of NK3R antagonist treatment. KP-10 was administered as an intravenous bolus at 6 hours with further frequent blood sampling for 2 hours.  Women self-reported the frequency and severity of hot flashes and the interference of those flashes with daily activities throughout the study. 





Figure 2. Gonadotropin response to administration of NK3R antagonist in healthy postmenopausal women (n=11). (A) LH concentrations during 7 day course of NK3R antagonist treatment (blood samples taken once daily) and (B) AUC LH during 6 hours of 10 minute LH sampling pre-treatment and on day 7 of NK3R antagonist administration. (C) FSH response to NK3R antagonist. Data are presented as mean ± SEM. * p<0.05 vs pre-treatment. 

Figure 3. Analysis of 6 hour LH secretory pattern on day 7 of NK3R antagonist treatment compared to control pre-treatment day in healthy postmenopausal women as a group (n=11) and in those experiencing hot flashes only (n=8). Illustrative LH pulse profile from two subjects (A-with no flashes and G-with flashes) undergoing 10 minute blood sampling for LH for 6 hour with no NK3R antagonist treatment (black circles) and on day 7 of NK3R antagonist treatment (red squares). Mean LH pulse frequency (B), basal (nonpulsatile) LH secretion (C), mass of LH per pulse (D), pulsatile LH secretion (E) and the relative orderliness/regularity of LH secretory pattern (F) on day 7 of NK3R antagonist treatment was compared to pre-treatment day in all postmenopausal women (n=11). Mean LH pulse frequency (H), basal (nonpulsatile) LH secretion (I), mass of LH per pulse (J), pulsatile LH secretion (K) and the relative orderliness/regularity of LH secretory pattern (L) on day 7 of NK3R antagonist treatment was compared to pre-treatment day in postmenopausal women reporting hot flashes (n=8). Data are presented as mean ± SEM. *, p<0.05; **, p<0.01. 




Figure 4. AUC LH (A) and AUC FSH (B) response to KP-10 injection with and without NK3R antagonist in postmenopausal women (n=10). AUC LH (sampling every 10 minutes) and AUC FSH (sampling every hour) were compared over one hour before KP-10 administration (i.e. after 6 hours) with 2 hours post KP-10 administration, before NK3R antagonist, and after 7 days of NK3R antagonist treatment during frequent blood sampling. Data are presented as mean ± SEM.


Figure 5. Differences in the frequency and severity score of menopausal hot flashes pre-treatment and during 7 days of NK3R antagonist administration (n=8). Response to NK3R antagonist is shown for individual postmenopausal women for the frequency of day (A) and night-time (B) hot flash and their severity (C), showing mean over 7 days before and during NK3R antagonist administration. Time-course in the reduction of mean day (D) and night-time (E) hot flash frequency over 7 days of NK3R antagonist administration is compared to mean of pre-treatment period. Data are presented as mean ± SEM.*, p<0.05; **, p<0.01 vs baseline. 









Hot Flash Interference	Pre-treatment (n=8)	NK3Ra (n=8)	p value
Total Hot Flash-Related Daily Interference Scale (HFRDIS) Score	31.3 (7.7)	9.0 (4.7)	0.008
Individual HFRDIS item responses (0-10; do not interfere-completely interfere)
Work Social activitiesLeisure activitiesSleepMoodConcentrationRelations with othersSexualityEnjoyment of lifeOverall quality of life	5.8 (1.1)5.5 (1.0)4.8 (0.9)6.4 (0.8)4.8 (0.8)5.8 (0.8)2.8 (1.1)4.8 (1.0)3.7 (0.8)4.2 (0.7)	1.8 (1.1)1.5 (1.2)1.5 (1.2)1.1 (0.6)1.4 (0.7)1.6 (0.7)0.3 (0.3)2.6 (1.2)1.2 (0.6)1.3 (0.6)	0.250.130.140.0080.060.060.250.250.060.06
Table 1. Differences in hot flash-related daily interference scale scores pre-treatment and during 7 days of NK3R antagonist administration. Total and individual item HFRDIS scores in 8 postmenopausal women are shown. Data are presented as mean ± SEM.
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